Real-time Tumor
Response Monitoring Test
Surgery, radiotherapy, chemotherapy
and combination of therapies
RadTox™ test indirectly detects cell death during and after cancer treatment by measuring the total cfDNA released from both normal and tumor cells. Unlike tumor-specific tests such as genomic profiling and MRD (molecular residual disease) monitoring, the RadTox™ test tells the overall treatment response trend regardless of cancer types and individual mutations based on hundreds of clinical publications.
Experience cancer care with RadTox™ Test that provides real-time response insights into your cancer therapy.
REAL-TIME
RadTox™, a simple blood test, gives you timely insights and peace of mind by eliminating the anxiety of weeks or even months of waiting for imaging results.
RESPONSE
RadTox™ test complements the existing standard care protocols and empowers physicians with invaluable information about their patient's disease progression, revolutionizing the way we monitor cancer treatment easily and consistently.
Monitoring cfDNA
Monitoring cfDNA levels during and after cancer treatments through our RadTox assay provides real-time information on cell death and tumor dynamics that can guide physicians to make optimal decisions within the context of other clinical and imaging information.
The baseline cfDNA level indicates the prognosis before treatment
cfDNA increases after treatment indicates disease progression (PD)
cfDNA keeps constant, indicates stable disease (SD)
cfDNA decreases indicate partial response (PR)
A higher ratio of the cfDNA after treatment over the baseline before treatment indicates poorer progression-free survival and overall survival
Clinical Cases
Case 1
A rectal cancer patient went through chemotherapy between May and July 2019. RaxTox monitoring started in May. The RadTox score reached its highest in late July and came down in early August. The RadTox score stayed stable until the last monitoring point in November. The patient remains in a stable condition.
Case 2
An esophageal cancer patient stabilized after treatment. RadTox score stayed low from February to August 2020. The esophageal cancer patient stabilized after treatment. The RadTox score stayed low from February to August 2020. Then, the RadTox score started to increase when the cancer recurrence occurred.
Case 3
The concentration of cfDNA in cancer patients changes dynamically at different time points, correlating to the imaging results for tumor size measurement and drug treatment responses. With the therapeutic intervention, the dynamic change of cfDNA concentration can indicate the patient's therapeutic efficacy: PR-SD (Partial Response - Stable Disease)
Case 4
The concentration of cfDNA in cancer patients changes dynamically at different time points, correlating to the imaging results for tumor size measurement and drug treatment responses. With the therapeutic intervention, the dynamic change of cfDNA concentration can indicate the patient's therapeutic efficacy: PR-SD-PD (Partial Response - Stable Disease - Disease Progression)
Clinical Applications
Monitoring of Transition from Progression of Disease to Stable Disease
Figure legend: The cfDNA concentrations of cancer patient 5036531 cfDNA vary at different time points.
The dynamic cfDNA data of 200 patients at different treatment time points were screened, and the cfDNA changes of patients with different treatment efficacy were reflected through the changes in the ratio of the treatment process and the highest peak to the post-treatment value of patients. The ratio of the highest peak/post-treatment value at different treatment times and the treatment process/post-treatment value were analyzed for ROC curve diagnosis. According to the ROC curve analysis,
the AUC (95% CI) under the ROC curve was 0.987 (0.893-0.999), the sensitivity was 96.43%, the specificity was 92.86%, and the optimal cut-off value was 3.90, indicating that when the cfDNA high-peak level at the PD stage dropped by 4-fold, the PD stage had transitioned to the SD stage.
Monitoring Transition from Stable Disease to Recurrence
Figure legend: The cfDNA concentrations of cancer patient 208910 vary at different time points.
The dynamic cfDNA data of 200 cancer patients at different treatment time points were screened, and the cfDNA changes of patients with different treatment efficacy were reflected through the changes of treatment process and the ratio of the highest peak to the baseline value of patients. The ratio of the highest peak/baseline value at different treatment times and the treatment process baseline value were analyzed for ROC curve diagnosis. According to ROC curve analysis,
the AUC (95% CI) under the ROC curve of the highest peak/baseline value ratio and the treatment course/baseline value to assist the diagnosis of patients with different cancers was 0.969 (0.884-0.997), the sensitivity was 96.43%, the specificity was 90.29%, and the optimal cut-off value was 3.64, indicating when cfDNA low-peak level at SD stage increases by 4-fold, the SD stage has transitioned to Recurrence stage.
